Applied InSilico Launches its Evolutionary Learning Environment, ELE.

CHIPPENHAM, U.K. -- ELE(TM) is the first non-proprietary self-learning analysis platform that automates preclinical drug discovery data.

Applied InSilico dramatically reduces time and resources during preclinical drug discovery by providing uncompromised insight into complex disease data. Their Evolutionary Learning Environment, ELE(TM), launched today, automates the preclinical drug discovery process by applying non-proprietary, intelligent algorithms within a highly adaptive learning environment.

The need to improve drug development is clear. According to Boston Consulting Group, developing one new drug takes 8-12 years and costs $800 million. In silico technologies are being employed to reduce preclinical R&D and late stage attrition due to adverse effects; producing more qualified drug candidates.

"Geneticists, biologists and chemists are adopting computational tools for their day-to-day analysis," explains Dr. Jay Perrett, Chief Technical Officer, Applied InSilico. "Our technology removes much of the analysis burden by revealing verifiable relationships in the most complex of datasets. Scientists can now apply their skills to using, rather than building, complicated models; resulting in a dramatic reduction in time and resources."

Applied InSilico's application platform, ELE, is an evolutionary learning and computation system designed to derive optimal algorithmic computational solutions for a variety of problems. There are three components:

1. ELEsimulator(TM) manages the distribution of problem data and simulated evolution automating the analysis process.

2. ELEprocessor(TM) responsible for processing problems on any available network machine.

3. ELEmodeller(TM) incorporates knowledge captured through solution evolution in a small distributable application.

Applied InSilico collaborates with innovative pharmaceutical and biotech companies to deliver solutions that reduce time and costs associated with target discovery. One such company, Celera Diagnostics, a joint venture between the Celera Genomics Group and Applied Biosystems Group of Applera Corporation, conducted a deep vein thrombosis study and found Applied InSilico produced accurate predictions of complex genotype-phenotype interactions. They presented a poster on the study at the American Society for Human Genetics meeting; view it at www.appliedinsilico.com.

Applied InSilico

Applied InSilico (www.appliedinsilico.com), a DNNI company, provides analytical solutions to various industry sectors. Applied InSilico has exclusive license to the technology in Life Sciences and provides uncompromised insight into complex disease data. It reveals verifiable relationships in the most complex of datasets, dramatically reducing time and resources to model data. The platform can be applied to a specific area of preclinical drug discovery or across the complete drug discovery pipeline.